Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 471,970 shares, a drop of 45.4% from the February 15th total of 865,047 shares. Based on an average daily trading volume, of 134,261 shares, the short-interest ratio is currently 3.5 days. Approximately 2.1% of the company’s stock are short sold.
Several large investors have recently modified their holdings of AGLE. Canada Pension Plan Investment Board bought a new position in shares of Aeglea Bio Therapeutics during the 4th quarter valued at $37,000. Meeder Asset Management Inc. raised its holdings in shares of Aeglea Bio Therapeutics by 44.9% during the 4th quarter. Meeder Asset Management Inc. now owns 5,116 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,585 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Aeglea Bio Therapeutics by 299.9% during the 4th quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,858 shares in the last quarter. Millennium Management LLC bought a new position in shares of Aeglea Bio Therapeutics during the 4th quarter valued at $156,000. Finally, Rhumbline Advisers raised its holdings in shares of Aeglea Bio Therapeutics by 48.7% during the 4th quarter. Rhumbline Advisers now owns 21,571 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 7,069 shares in the last quarter. 68.43% of the stock is owned by institutional investors.
Shares of NASDAQ:AGLE opened at $8.31 on Friday. The firm has a market cap of $241.22 million, a price-to-earnings ratio of -3.90 and a beta of 1.07. Aeglea Bio Therapeutics has a 12-month low of $6.31 and a 12-month high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.27). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 71.39%. Equities research analysts expect that Aeglea Bio Therapeutics will post -1.7 earnings per share for the current fiscal year.
A number of brokerages have issued reports on AGLE. ValuEngine raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 5th. Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research note on Thursday, January 3rd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Aeglea Bio Therapeutics currently has an average rating of “Buy” and an average price target of $21.75.
WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/15/aeglea-bio-therapeutics-inc-agle-short-interest-update.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Story: Why is cost of goods sold important?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.